

| | | | |
|--|--|---------------------------------|----------------------------|
| FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office | | Attorney Docket No. | Client Ref. |
| | | 056291-5199 | 107523838 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Applicant: Stephen Robert WEDGE | |
| | | Appl. No.: To Be Assigned | |
| | | Filing Date: Concurrently | |
| Date: February 8, 2005 | | Examiner: Unassigned | Group Art Unit: Unassigned |

| U.S. PATENT DOCUMENTS | | | | | | | | |
|-----------------------|----|-----------------|--------------|--------------------------------------|-------|-----------|------------------------------|--|
| Examiner's Initials* | | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date (if appropriate) | |
| | AR | | | | | | | |
| | BR | | | | | | | |
| | CR | | | | | | | |
| | DR | | | | | | | |
| | ER | | | | | | | |
| | FR | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | English Abstract | Translation Readily Available | | | |
|--------------------------|----|-----------------|--------------|---------|-------------------------|-------------------------------|----|----------|----|
| | | Document Number | Date MM/YYYY | Country | Inventor/Applicant Name | Enclosed | No | Enclosed | No |
| | GR | | | | | | | | |
| | HR | | | | | | | | |
| | IR | | | | | | | | |
| | JR | | | | | | | | |
| | KR | | | | | | | | |
| | LR | | | | | | | | |
| | MR | | | | | | | | |
| | NR | | | | | | | | |

| | | | | | | | | | |
|--|----|--|--|--|--|--|--|--|--|
| OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | | | | | | | |
| /C.S./ | OR | Magné et al., British Journal of Cancer, vol. 86, No. 5, 4 March 2002, pp. 819-827 | | | | | | | |
| /C.S./ | PR | Ciardiello et al., Clinical Cancer Research, The American Association for Cancer Research, vol. 6, no. 5, May 2000, pp. 2053-2063 | | | | | | | |
| /C.S./ | QR | Holden et al., European Journal of Cancer, vol. 37, no. Supplement 6, October 2001, p. S73 | | | | | | | |
| /C.S./ | RR | Hennequin et al., Journal of Medicinal Chemistry, vol. 45, no. 6, 14 March 2002, pp. 1300-1312 | | | | | | | |
| /C.S./ | SR | "Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR 'KDRI-TKI), in a model of ZD1839 ('Iressa') resistance", European Journal of Cancer, vol. 38, November 2002, pp. S60-S61 | | | | | | | |
| /C.S./ | TR | Manley et al., Expert Opinion on Investigational Drugs, vol. 11, no. 2, Dec. 2002, pp. 1715-1736 | | | | | | | |
| | UR | | | | | | | | |
| | VR | | | | | | | | |

| | |
|--|-----------------------------|
| Examiner /Christopher Stone/ | Date Considered: 10/11/2007 |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. | |